FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071598404> ?p ?o ?g. }

• W2071598404 endingPage "423" @default.
• W2071598404 startingPage "423" @default.
• W2071598404 abstract "In my recent review article 1, I chose a topic that not only represents the rapidly moving field of cancer immunotherapy, but also tells an interesting story. The role of CD4+ T cells and MHC class I- and II-restricted antigens (Ags) from solid tumors, especially melanoma, was focused on because: (1) melanoma is the best-studied human tumor model for immunotherapy; and (2) the majority of MHC class II-restricted tumor Ags identified to date are melanoma Ags. The availability of such Ags has led to many clinical trials as well as animal studies. These studies indicate a requirement for CD4+ T cells and MHC class II-restricted tumor Ags for optimal antitumor immunity. By contrast, relatively few tumor Ags from hematological malignancies, such as chronic myelogenous leukemia (CML), have been identified. As a result, I did not cite MHC class II-restricted T-cell peptides from CML in the article, but this was not intended to imply that these MHC class II-restricted peptides are not important. I do not disagree with the comments of Pawelec et al. that MHC class II-restricted Ags or epitopes derived from the fusion proteins BCR–ABL or ABL–BCR are very important. In particular, like the LDFP fusion protein generated by fusing a low-density lipid receptor (LDLR) to a GDP-l-fucose:β-d-galactose 2-α-l-fucosyltransferase (FUT) in an antisense orientation 2, these fusion Ags resulting from chromosomal rearrangement are excellent tumor-specific targets for the immunotherapy of CML. However, the evidence for the other class II-restricted Ags mentioned by Pawelec et al. is not convincing; data on CD4+ T-cell responses to MHC class II-restricted peptides of WT1 were not provided in the original article 3. In addition, defensins appear to function as self-peptides with the ability to bind to MHC class II molecules that inhibit, rather than stimulate, CD4+ T-cell responses 4. Thus, it is not clear if defensins are true MHC class II-restricted tumor Ags." @default.
• W2071598404 created "2016-06-24" @default.
• W2071598404 creator A5070717343 @default.
• W2071598404 date "2001-08-01" @default.
• W2071598404 modified "2023-09-24" @default.
• W2071598404 title "MHC class II-restricted tumor antigens and CD4+ T cells play a role in hematological malignancies as well as solid tumors" @default.
• W2071598404 cites W1549439067 @default.
• W2071598404 cites W2111538203 @default.
• W2071598404 cites W2115182182 @default.
• W2071598404 cites W2119355700 @default.
• W2071598404 cites W2149912943 @default.
• W2071598404 cites W2155362903 @default.
• W2071598404 cites W236447865 @default.
• W2071598404 doi "https://doi.org/10.1016/s1471-4906(01)01986-x" @default.
• W2071598404 hasPublicationYear "2001" @default.
• W2071598404 type Work @default.
• W2071598404 sameAs 2071598404 @default.
• W2071598404 citedByCount "1" @default.
• W2071598404 countsByYear W20715984042020 @default.
• W2071598404 crossrefType "journal-article" @default.
• W2071598404 hasAuthorship W2071598404A5070717343 @default.
• W2071598404 hasConcept C147483822 @default.
• W2071598404 hasConcept C170627219 @default.
• W2071598404 hasConcept C188280979 @default.
• W2071598404 hasConcept C203014093 @default.
• W2071598404 hasConcept C207936829 @default.
• W2071598404 hasConcept C2776960273 @default.
• W2071598404 hasConcept C2777658100 @default.
• W2071598404 hasConcept C2777701055 @default.
• W2071598404 hasConcept C2778461978 @default.
• W2071598404 hasConcept C2778814158 @default.
• W2071598404 hasConcept C2780674031 @default.
• W2071598404 hasConcept C502942594 @default.
• W2071598404 hasConcept C71924100 @default.
• W2071598404 hasConcept C86803240 @default.
• W2071598404 hasConcept C8891405 @default.
• W2071598404 hasConceptScore W2071598404C147483822 @default.
• W2071598404 hasConceptScore W2071598404C170627219 @default.
• W2071598404 hasConceptScore W2071598404C188280979 @default.
• W2071598404 hasConceptScore W2071598404C203014093 @default.
• W2071598404 hasConceptScore W2071598404C207936829 @default.
• W2071598404 hasConceptScore W2071598404C2776960273 @default.
• W2071598404 hasConceptScore W2071598404C2777658100 @default.
• W2071598404 hasConceptScore W2071598404C2777701055 @default.
• W2071598404 hasConceptScore W2071598404C2778461978 @default.
• W2071598404 hasConceptScore W2071598404C2778814158 @default.
• W2071598404 hasConceptScore W2071598404C2780674031 @default.
• W2071598404 hasConceptScore W2071598404C502942594 @default.
• W2071598404 hasConceptScore W2071598404C71924100 @default.
• W2071598404 hasConceptScore W2071598404C86803240 @default.
• W2071598404 hasConceptScore W2071598404C8891405 @default.
• W2071598404 hasIssue "8" @default.
• W2071598404 hasLocation W20715984041 @default.
• W2071598404 hasOpenAccess W2071598404 @default.
• W2071598404 hasPrimaryLocation W20715984041 @default.
• W2071598404 hasRelatedWork W2070030959 @default.
• W2071598404 hasRelatedWork W2138679099 @default.
• W2071598404 hasRelatedWork W2168688111 @default.
• W2071598404 hasRelatedWork W2271674799 @default.
• W2071598404 hasRelatedWork W2285621780 @default.
• W2071598404 hasRelatedWork W2808202755 @default.
• W2071598404 hasRelatedWork W2982049472 @default.
• W2071598404 hasRelatedWork W3006929888 @default.
• W2071598404 hasRelatedWork W4286111395 @default.
• W2071598404 hasRelatedWork W4291452737 @default.
• W2071598404 hasVolume "22" @default.
• W2071598404 isParatext "false" @default.
• W2071598404 isRetracted "false" @default.
• W2071598404 magId "2071598404" @default.
• W2071598404 workType "article" @default.